Rajiv Jayadevan, MD
Urology · Los Angeles, CANPI 1477948800
Payments from drug & device makers
What this record shows
This record is dominated by grants: $51,181 of the $70,144 with a category attached, or 73.0%. Boston Scientific accounts for 76.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $51,096 and has fallen 82.7% since, to $8,863 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $531.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$54K
- Endo USA, Inc.$8K
- Procept Biorobotics Corporation$5K
- Coloplast$1K
- Endo Pharmaceuticals Inc.$998
- Antares Pharma, Inc.$396
- plus $1K from 11 others
What the payments were for
- Consulting fees$9,87514%
- Grants$51,18173%
- Travel & lodging$1,7923%
- Food & beverage$7,29610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 41 | $53,728 |
| Endo USA, Inc. | 12 | $7,980 |
| Procept Biorobotics Corporation | 18 | $4,629 |
| Coloplast | 13 | $1,349 |
| Endo Pharmaceuticals Inc. | 10 | $998 |
| Antares Pharma, Inc. | 9 | $396 |
| Teleflex LLC | 6 | $258 |
| Olympus America Inc. | 2 | $230 |
| AbbVie | 9 | $221 |
| Innovation Technologies Inc | 2 | $141 |
| BD | 3 | $65 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $46 |
| Halozyme Inc | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| 180 Medical, Inc. | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $18 |
| Urogen Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$50,000
- XIAFLEX$8,660
- AquaBeam Robotic System$4,244
- TITAN$1,220
- AMS 700 CXR RTE KIT$864
- AdVance XP$280
- AMS 700$258
- iTIND System$230
- EDEX$167
- AVEED$167
- Irrisept$133
- NOCDURNA$123
- XYOSTED$123
- TLANDO$123
- TACTRA$120
- Advantage System$108
- AMS AMBICOR$103
How this compares
$70,144 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 67 | $53,432 |
| MyrbetriqMirabegron | 17 | $15,355 |
| Testosterone | 48 | $6,975 |
| Testosterone Cypionate | 74 | $3,684 |
| Tamsulosin Hcl | 97 | $1,743 |
| Trospium Chloride | 12 | $1,408 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 50 | $1,229 |
| Methenamine Hippurate | 16 | $831 |
| Finasteride | 48 | $631 |
| Bupropion XlBupropion Hcl | 15 | $553 |
| Sildenafil Citrate | 21 | $382 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $150 |
| Meloxicam | 16 | $13 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $23 | $53,43267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.